Infusion refers to the slow delivery of a therapy directly into the bloodstream over a period of time. The decision shortens the twice-yearly infusion time to a two-hour session from the previously approved 3.5 hours. This may ease Ocrevus’ administration burden for patients and have a positive impact on healthcare resources.
“More than 170,000 people with MS have been treated with Ocrevus — the only approved B-cell therapy with a twice-yearly dosing schedule — and it is the most prescribed MS medicine in the U.S.,” Levi Garraway, MD, PhD, chief medical officer and head of global product development at Genentech, said in a press release. A subsidiary of Roche, Genentech is the developer of Ocrevus.
“We constantly strive to improve the experience that patients and their physicians have with our medicines, and we believe people with relapsing and primary progressive MS will find the shorter two-hour Ocrevus infusion time to be more convenient,” Garraway said.
Ocrevus is an anti-CD20 monoclonal antibody that works by targeting mature B-cells, a type of immune cell that drives the inflammation that damages the nervous system in MS.
Ocrevus’ dosing schedule involves two 300 mg infusions, given two weeks apart, followed by 600 mg infusions every six months. As per the conventional infusion time, the therapy is typically administered over 3.5 hours.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?